- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06654557
Effect of Adding Glycerol to Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest
The results of a prior study PEP-2311 suggested there was a positive dose-response effect of glycerol and sodium on fluid balance and fluid retention. In addition, inclusion of glycerol resulted in an upward shift in the relationship between sodium concentration and fluid balance. The practical interpretation is that addition of glycerol enables a reduction in sodium concentration compared with a 0% glycerol drink.
In this follow-up study, the investigators hypothesize that 1) fluid balance will be sustained (greater than or not different from baseline) and significantly greater than placebo for 120 min after drinking the test no/low/moderate carbohydrate beverages and 2) fluid balance will not differ between the carbohydrate-electrolyte beverages, but both will be greater than placebo.
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)
- Other: 0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)
- Other: 0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)
- Other: 6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)
- Other: 1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)
- Other: 6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)
- Other: 2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)
Detailed Description
This is a two-part study. Subjects will be asked to complete either Part 1 or Part 2 of this study. Subjects can participate in both parts of the study if they are interested and available to complete all trials. However, they will be asked to complete Part 1 before enrolling in Part 2 of the study. Dosing days are separated by 2-15 days.
Objective 1) To compare the effect of consumption of four no/low/moderate carbohydrate drinks with high electrolyte concentrations vs. placebo on fluid balance at rest. To enroll N=25
Objective 2) To compare the effect of consumption of two moderate carbohydrate drinks with low electrolyte concentrations vs. placebo on fluid balance at rest. To enroll N=70
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lindsay Baker, PhD
- Phone Number: 814-883-9454
- Email: lindsay.baker@pepsico.com
Study Locations
-
-
New York
-
Valhalla, New York, United States, 10595
- Recruiting
- PepsiCo R&D, Gatorade Sports Science Institute
-
Contact:
- Matthew Hinkley, PhD
- Phone Number: 914-742-4975
- Email: Matt.Hinkley@pepsico.com
-
Contact:
- Lindsay Baker, PhD
- Phone Number: 814-883-9454
- Email: lindsay.baker@pepsico.com
-
Principal Investigator:
- Lindsay Baker, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subject is male or female
- If female, subject is not pregnant (based on self-report)
- Subject is 18-50 years of age, inclusive Subject is at least recreationally active (engaged in light to moderate intensity, intermittent, or steady-state exercise at least 3 days per week for at least 30 min at a time)
- Subject does not smoke (or has quit for at least 6 months)
- Subject is not taking medication that may interfere with the study (e.g., diuretics)
- Subject has no health conditions that would interfere with the study, As indicated on the general health questionnaire (GHQ), e.g. cardiovascular, renal, or metabolic diseases
- Subject is not allergic to adhesives (e.g., medical tape)
- Subject is not allergic to kiwi-strawberry flavoring
- Subject is willing to avoid alcohol consumption 24 hours prior to visit(s)
- Subject is willing to fast overnight (~8-12 hours)
- Subject is willing to refrain from vigorous exercise for 24 hours (light physical activity only)
- Subject is willing to eat the exact same food the day prior to each visit to the laboratory
- Able to speak, write, and read English
- Provision of written consent to participate
Exclusion Criteria:
- Subject has participated in a clinical trial within the past 30 days
- Subject has participated in any PepsiCo trial within past 6 months
- Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk
- Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
|
Experimental: 0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
|
Experimental: 6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
|
Placebo Comparator: Placebo beverage (Parts 1 and 2)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
|
|
Experimental: 1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
|
Experimental: 6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
|
Experimental: 2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)
|
9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
Beverage matched to placebo for color and flavor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fluid balance (Body Weight)
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Platform scale to the nearest 0.005 kilograms (kg)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Fluid balance (Percent (%) change in Body Mass)
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Platform scale to the nearest 0.005 kilograms (kg)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fluid retention
Time Frame: % change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Platform scale to the nearest 0.005 kilograms (kg), unit percent (%)
|
% change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Urine mass
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Graduated cylinder on scale to the nearest 0.01 grams
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Urine specific gravity
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
USG digital pen refractometer (Atago), no unit
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Blood sodium
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Fingerstick sampling, unit millimoles per liter (mmol/L), iSTAT Blood Electrolyte and Chemistry Analyzer (CHEM8+ cartridge)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Blood glucose
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Fingerstick sampling, unit milligrams per deciliter (mg/dl), iSTAT Blood Electrolyte and Chemistry Analyzer (CHEM8+ cartridge)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Percent change in plasma volume
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Fingerstick sampling, calculated from hematocrit and hemoglobin concentration percent (%)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Serum glycerol concentration
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Fingerstick sampling unit millimoles per liter (mmol/L) using Sigma Aldrich glycerol assay kit
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Serum osmolality
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Fingerstick sampling, unit milliosmoles per kilogram of water (mOsm/Kg H20)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Saliva osmolality
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Measured directly from the tongue using a handheld MX3 Diagnostics device, unit milliosmoles per kilogram of water (mOsm/kg H2O)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Blood pressure (systolic/diastolic)
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Automatic sphygmomanometer unit millimeters of mercury (mm/Hg)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Heart rate
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Heart rate monitor, unit beats per minute (bpm)
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Subjective measure of headache
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
One item on a 100 point visual analog scale anchored from 0=No headache to 100=Severe headache
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Subjective measure of lightheadedness
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
One item on a 100 point visual analog scale anchored from 0=No lightheadedness to 100=Severe lightheadedness
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Subjective measures of gastrointestinal discomfort
Time Frame: Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
Eight items on a 100 point visual analog scale (stomach upset, nausea, burping, stomach bloating, abdominal discomfort, stomach fullness, vomiting, diarrhea anchored frrom 0= None to 100=Severe
|
Change each test day from pre-beverage baseline (-60 minutes) to post-beverage Time 0 minutes, 30 minutes, 60 minutes, 90 minutes,120 minutes, and 150 minutes post 3rd (last) beverage
|
|
Menstrual categorization
Time Frame: Assessed at Screening Visit
|
Using Elliott-Sale chart, 2023 to categorize menstrual/hormonal contraceptive status for those who have not yet reached perimenopause/menopause.
This is a decision-tree chart, not a scale.
|
Assessed at Screening Visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lindsay Baker, PhD, PepsiCo R&D Life Sciences, Sports Science
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEP-2412
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluid Balance
-
PepsiCo Global R&DRecruitingFluid BalanceUnited States
-
PepsiCo Global R&DRecruiting
-
Attikon HospitalUnknown
-
Nantes University HospitalCompletedFluid Overload | Fluid Balance of ICU PatientsFrance
-
Asir John SamuelCompletedCryotherapy Effect | Balance; Disorder, FluidIndia
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedUrinary Catheters | Diuresis | Fluid Balance | Automated Urine Monitoring | Urine OutputNetherlands
-
University of California, DavisBayerCompletedWounds and Injuries | Multiple Trauma | Disorder of Fluid BalanceUnited States
-
University of ConnecticutUnited States Department of Defense; AMP Human; Park City, UTCompletedCognitive Change | Electrolyte and Fluid Balance Conditions | Fluid Retention | Heat Exposure | Fluid Loss | Hyperhydration | Sodium RetentionUnited States
-
Assiut UniversityUnknownChest Trauma | Fluid Balance; Disorder
-
Masarykova Nemocnice v Usti nad Labem, Krajska...Not yet recruitingWeight Change | Fluid Balance | Weight Bias | Fluid Accumulation
Clinical Trials on Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)
-
PepsiCo Global R&DRecruitingFluid BalanceUnited States
-
Novartis PharmaceuticalsCompletedPrimary Biliary CholangitisUnited States, Germany, Russian Federation, Canada, United Kingdom, Poland
-
Janssen Research & Development, LLCCompletedHealthy | Asthma | Atopic DermatitisGermany, Belgium
-
Chiesi Farmaceutici S.p.A.CompletedCystic Fibrosis | Non-Cystic Fibrosis BronchiectasisBelgium
-
Chiesi Farmaceutici S.p.A.TerminatedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Akesobio Australia Pty LtdCompletedAtopic DermatitisNew Zealand, Australia
-
Tetherex Pharmaceuticals CorporationCompletedChronic Obstructive Pulmonary Disease | AsthmaUnited Kingdom
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.CompletedModerate to Severe Atopic DermatitisUnited States, Canada, Czechia, Germany, Poland
-
UCB PharmaParexelCompleted
-
Klotho Sciences Australia Pty Ltd.Not yet recruitingAlzheimer Disease | Chronic Kidney Disease | Healthy ParticipantsAustralia